http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2401996-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68c7394ae62160df902f342a842769df |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2009-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_359e524c99e0d5b546e25e0a578a2443 |
| publicationDate | 2013-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2401996-T3 |
| titleOfInvention | Procedure for preclinical tests of immunomodulatory drugs |
| abstract | Method for testing an immunomodulatory drug under study or known for the activation of T lymphocytes, which comprises the step of in vitro contacting a culture of peripheral blood mononuclear cells (PBMC) with a predetermined amount of the immunomodulatory drug under study or known and observe the culture of PBMC to determine the release of at least one cytokine from the PBMC or to determine cell proliferation after contacting the immunomodulatory drug under study or known, in which the cell density of a PBMC preculture during and / or after the preculture stage is at least 2 * 106 / ml or at least 4 * 105 / cm2 so that cell-cell contact of the PBMC is allowed, and in which the PBMC preculture is cultured for at least 12 h. |
| priorityDate | 2009-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 230.